MBBS, FRACP, PRCP (UK)
Prof Goldstein is a Conjoint Clinical Professor. He has been involved in a variety of clinical research projects ranging from laboratory basic science to novel therapeutics trials to psychosocial aspects of Cancer care. He has been PI of a number of NHMRC and Cancer Australia funded therapeutic trials including both investigator initiated and as Australian PI for multinational studies. He has also been involved with psychosocial and cross cultural/CALD research for many years. His clinical interests are treatment of GI malignancies including pancreas cancer, colorectal cancer, anal carcinoma, hepatobilary and upper GI malignancy and renal cell carcinoma and lymphoma.
Prof Goldstein has been a Chief or Principal Investigator on $39,000,000 peer reviewed funded grants. He was the Director of the UNSW Translational Cancer Research Network, a $6,000,000 5 year CINSW funded program now completed. He was the adult program leader of the UNSW National Cancer Survivors Centre and is involved with a research program associated with survivorship issues. As part of this activity, he was the Chief Investigator of a 5 year Cancer Institute NSW translational program grant of $3,100,000 to study the impact of chemotherapy induced peripheral neuropathy, now completed.
He also actively participates in two laboratory research programs dealing with stromal biology, pancreas drug resistance and modelling optimal targeted therapies.
Prof Goldstein has 370 co-authored peer reviewed publications, since 2017 citations 17460, overall 33917, H index 80, since 2017 56 [Google Scholar]. He has presented at numerous national and international meetings: ESMO- ESMO Asia, ESMO GI, USA – ASCO, Japan - Japan Pancreas Society, Gastro week and medical oncology group, New Zealand, S. Korea, Singapore, COSA ASM.
National and international collaborations with researchers at University of Sydney, MRC (UK), University of Liverpool, GERCOR, NCIC. Invited reviewer for leading scientific journals, and grant applications (NHMRC, ARC).
AGITG JOHN ZALCBERG AWARD FOR CLINICAL RESEARCH EXCELLENCE
CANCER INSTITUTE NSW MAKE A DIFFERENCE AWARD
PEOPLES HEALTH MEDAL VIETNAM
Prof Goldstein has extensive clinical trial experience in both design and leadership. He also participated in a number of translational studies and is an active collaborator in three laboratory programs focused upon modeling of the use of targeted agents. His activity over many years in one of the least common cancers and least studied, until recently, in the GI area – pancreas cancer, as well as GIST and biliary cancers gives him great insight into the challenges of approaching a suite of rare cancers. He has also been involved in several large scale epidemiologic studies, the most recent looking at pancreatic cancer. He has contributed to pivotal data resulting in PBS changes in approval for adjuvant gemcitabine in pancreas cancer, imatinib in metastatic and adjuvant GIST and first line nab-paclitaxel in pancreatic cancer.
My Research Supervision
cosupervising 2x PhD in pancreatic cancer biology, one in pancreatic cancer translational science